Europe Viscosupplementation Market, By Type (Single Injection, Cycle Three Injection Cycle, Five Injection Cycle), By End User (Hospitals, ASCs, Clinics), By Country (Western Europe (Germany, UK, France, Italy, Spain, Nordic Countries, Rest of Western Eur

Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan for therapeutic purposes, the rheological properties (viscosity and elasticity) are low, and therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions and has comparable rheological properties to those of the fluid found in young, healthy individuals.

Market Dynamics

The key market players are focusing on the adoption of growth strategies such as partnerships and product launches, which is attributed to the growth of the Europe viscosupplementation market. For instance, in May 2022, Fidia Farmaceutici S.p.A., produces medical products and offers hyaluronic acid products for intra-articular injection, hyaluronic acid treatments used in tissue repair to treat general wounds, ulcers, bedsores, and topical treatment of burns and skin lesions in Italy, launched its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo held in 2022. The company launched its complete Hyal System and Hy-Tissue portfolio in Spain. This helped the company to showcase its research for hyaluronic acid in Spain.

Key features of the study:

• This report provides an in-depth analysis of Europe viscosupplementation market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Europe viscosupplementation market based on the following parameters– Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include include Sanofi S.A., Anika Therapeutics, Inc., Seikagaku, Zimmer Biomet Holdings Inc., Meda AB (Mylan), Fidia Farmaceutici S.p.A., Bioventus LLC, Ferring B.V, Lifecore Biomedical, OrthogenRx, Inc. (a subsidiary of AVNS), APTISSEN, Johnson & Johnson Services, Inc., Viatris Inc., IBSA Institut Biochimique SA, Ortobrand International, TRB CHEMEDICA SA, Teva Pharmaceutical Industries Ltd., Lifecore (a subsidiary of Landec Corporation), VIRCHOW BIOTECH, Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals), and LG Life Sciences.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Europe viscosupplementation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe viscosupplementation market

• Europe Viscosupplementation Market, By Type:
• Single Injection Cycle
• Three Injection Cycle
• Five Injection Cycle
• Europe Viscosupplementation Market, By End User:
• Hospitals
• ASCs
• Clinics
• Europe Viscosupplementation Market, By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Company Profiles
• Sanofi S.A.
• Anika Therapeutics, Inc.
• Seikagaku
• Zimmer Biomet Holdings Inc.
• Meda AB (Mylan)
• Fidia Farmaceutici S.p.A.
• Bioventus LLC
• Ferring B.V
• Lifecore Biomedical
• OrthogenRx, Inc. (a subsidiary of AVNS)
• APTISSEN
• Johnson & Johnson Services, Inc.
• Viatris Inc.
• IBSA Institut Biochimique SA
• Ortobrand International
• TRB CHEMEDICA SA
• Teva Pharmaceutical Industries Ltd.
• Lifecore (a subsidiary of Landec Corporation)
• VIRCHOW BIOTECH
• Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals)
• LG Life Sciences